ATYR

Company Overview — What Does aTYR PHARMA INC Do?

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California. aTYR PHARMA INC (ATYR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sanjay S. Shukla and employs approximately 53 people, headquartered in SAN DIEGO, California. With a market capitalization of $83M, ATYR is one of the notable companies in the Healthcare sector.

aTYR PHARMA INC (ATYR) Stock Rating — Avoid (April 2026)

As of April 2026, aTYR PHARMA INC receives a Avoid rating with a composite score of 24.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ATYR ranks #4,178 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, aTYR PHARMA INC ranks #744 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ATYR Stock Price and 52-Week Range

aTYR PHARMA INC (ATYR) currently trades at $0.84. The stock gained $0.09 (12.0%) in the most recent trading session. The 52-week high for ATYR is $7.29, which means the stock is currently trading -88.5% from its annual peak. The 52-week low is $0.64, putting the stock 31.2% above its annual trough. Recent trading volume was 981K shares, suggesting relatively thin trading activity.

Is ATYR Overvalued or Undervalued? — Valuation Analysis

aTYR PHARMA INC (ATYR) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.16x, versus the sector average of 2.75x. The price-to-sales ratio is 410.32x, compared to 1.66x for the average Healthcare stock.

At current multiples, aTYR PHARMA INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

aTYR PHARMA INC Profitability — ROE, Margins, and Quality Score

aTYR PHARMA INC (ATYR) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -115.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -83.2% versus the sector average of -33.1%.

The operating margin is -14076.3% (sector: -66.1%). Net profit margin stands at -13550.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ATYR Debt, Balance Sheet, and Financial Health

aTYR PHARMA INC has a debt-to-equity ratio of 38.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.30x, indicating strong short-term liquidity. Total debt on the balance sheet is $398,000. Cash and equivalents stand at $6M.

ATYR has a beta of 1.05, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for aTYR PHARMA INC is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

aTYR PHARMA INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, aTYR PHARMA INC reported revenue of $190,000 and earnings per share (EPS) of $-0.80. Net income for the quarter was $-77M. Operating income came in at $-81M.

In FY 2025, aTYR PHARMA INC reported revenue of $190,000 and earnings per share (EPS) of $-0.80. Net income for the quarter was $-74M. Revenue grew -19.1% year-over-year compared to FY 2024. Operating income came in at $-78M.

In Q3 2025, aTYR PHARMA INC reported revenue of $190,000 and earnings per share (EPS) of $-0.26. Net income for the quarter was $-26M. Operating income came in at $-27M.

In Q2 2025, aTYR PHARMA INC reported revenue of $0 and earnings per share (EPS) of $-0.22. Net income for the quarter was $-20M. Operating income came in at $-20M.

Over the past 8 quarters, aTYR PHARMA INC has demonstrated a growth trajectory, with revenue expanding from $0 to $190,000. Investors analyzing ATYR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ATYR Dividend Yield and Income Analysis

aTYR PHARMA INC (ATYR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ATYR Momentum and Technical Analysis Profile

aTYR PHARMA INC (ATYR) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

ATYR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, aTYR PHARMA INC (ATYR) ranks #744 out of 838 stocks based on the Blank Capital composite score. This places ATYR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ATYR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ATYR vs S&P 500 (SPY) comparison to assess how aTYR PHARMA INC stacks up against the broader market across all factor dimensions.

ATYR Next Earnings Date

No upcoming earnings date has been announced for aTYR PHARMA INC (ATYR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ATYR? — Investment Thesis Summary

The quantitative profile for aTYR PHARMA INC suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 27/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, aTYR PHARMA INC (ATYR) earns a Avoid rating with a composite score of 24.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ATYR stock.

Related Resources for ATYR Investors

Explore more research and tools: ATYR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ATYR head-to-head with peers: ATYR vs AZN, ATYR vs SLGL, ATYR vs VMD.